U.S. markets open in 6 hours 42 minutes

Sanofi (SNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
50.20-0.93 (-1.82%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close51.13
Bid0.00 x 800
Ask0.00 x 900
Day's Range50.13 - 51.58
52 Week Range37.62 - 55.00
Avg. Volume1,126,847
Market Cap125.136B
Beta (5Y Monthly)0.35
PE Ratio (TTM)25.88
EPS (TTM)1.94
Earnings DateN/A
Forward Dividend & Yield1.70 (3.32%)
Ex-Dividend DateApr 30, 2020
1y Target Est61.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-14% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Sanofi: Information concerning the total number of voting rights and shares - October 2020

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)Sanofi a French société anonyme with a registered share capital of 2,517,873,886 € Registered office : 54, rue La Boétie – 75008 Paris – France Registered at the Paris Commercial and Companies Registry under number 395 030 844Date   Total number of issued shares   Number of real voting rights (excluding treasury shares) Theoretical number of voting rights (including treasury shares)* October 31, 2020 1,258,964,700 1,411,078,975 1,413,674,734 *  Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.This information is also available on the internet website of sanofi under « Regulated Information in France »:https://www.sanofi.com/en/investors/sanofi-share-and-adrs/share-overview/shares-and-voting-rights/Investor Relations Department Europe Tel: + 33 1 53 77 45 45           US Tel: + 1 908 981 5560 e-mail: IR@sanofi.com   Media Relations Department Tel: + 33 1 53 77 46 46  e-mail: MR@sanofi.com    Attachment * EN_number_of_shares_and_voting_rights_October_2020

  • GlobeNewswire

    Sanofi: Disclosure of trading in own shares

    Disclosure of trading in own shares from November 23, 2020 to November 27, 2020Attachment * 2020_11_27_Reporting_action_SANOFI_EN

  • Regeneron (REGN), Sanofi Win EC Nod for Dupixent Label Expansion

    Regeneron (REGN), Sanofi Win EC Nod for Dupixent Label Expansion

    Regeneron (REGN) and Sanofi win EC nod for Dupixent for the indication of severe atopic dermatitis in children 6 to 11 years of age.